The effect of carnitin supplementation in hemodialysis patients
Not Applicable
Completed
- Conditions
- Hemodilysis.Care involving dialysis
- Registration Number
- IRCT2013070913160N2
- Lead Sponsor
- niversity of Medical Sciences,yazd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
patients on hemodialysis in last year; age older than 21 years old and did not take antibiotics; vitamin C, vitamin E, carnitine during last 8 weeks. Exclusion criteria: if a patients suffering from an infection diease or fever in last month or is taking antibiotics.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eptin. Timepoint: Baseline, end of thirth month. Method of measurement: ELISA.;Adiponectin. Timepoint: Baseline, end of thirth month. Method of measurement: ELISA.;Total anti oxidant capicity. Timepoint: Baseline, end of thirth month. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link carnitine supplementation to adiponectin and leptin modulation in hemodialysis patients?
How does carnitine supplementation compare to standard-of-care treatments in improving antioxidant capacity for hemodialysis patients?
Which biomarkers are associated with carnitine response in hemodialysis patients with altered adiponectin/leptin levels?
What are the potential adverse events of carnitine supplementation in chronic hemodialysis populations and how are they managed?
Are there combination therapies involving carnitine that enhance antioxidant capacity in end-stage renal disease patients undergoing dialysis?